PUMA BIOTECHNOLOGY, INC.

For the period ended Sep 30, 2026. Filed Nov 9, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2026 · Filed Nov 9, 2026

PBYI$8.40+1.8%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Item 1. Condensed Consolidated Statements of Operations for the Three and Nine Months Ended September 30, 2026 and 2025

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(in thousands, except share and per share data)

· · For the Three Months Ended September 30, · · · For the Nine Months Ended September 30, ·
· · 2026 · · · 2025 · · · 2026 · · · 2025 ·
Revenues:
Product revenue, net	$54,112	$51,902	$149,631	$144,194
Royalty revenue	944	2,573	6,741	8,724
Total revenue	55,056	54,475	156,372	152,918
Operating costs and expenses:
Cost of sales	15,198	12,173	38,097	35,030
Selling, general and administrative	16,301	16,817	52,271	52,468
Research and development	18,283	15,912	56,973	45,227
Total operating costs and expenses	49,782	44,902	147,341	132,725
Income from operations	5,274	9,573	9,031	20,193
Other income (expenses):
Interest income	879	1,044	2,712	3,101
Interest expense	—	(1,489)	(911)	(5,503)
Other income	19	115	158	884
Total other income (expenses), net	898	(330)	1,959	(1,518)
Net income before income taxes	$6,172	$9,243	$10,990	$18,675
Income tax expense	(216)	(399)	(598)	(1,002)
Net income	$5,956	$8,844	$10,392	$17,673
Net income per share of common stock—basic	$0.12	$0.18	$0.20	$0.35
Net income per share of common stock—diluted	$0.11	$0.17	$0.20	$0.35
Weighted-average shares of common stock outstanding—basic	51,602,295	50,339,456	51,131,897	49,881,181
Weighted-average shares of common stock outstanding—diluted	53,116,836	50,929,893	52,605,014	50,334,553

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

(in thousands)

	For the Three Months Ended September 30,		For the Nine Months Ended September 30,
	2026	2025	2026	2025
Net income	$5,956	$8,844	$10,392	$17,673
Other comprehensive income (loss):
Unrealized (loss) gain on available-for-sale securities, net of tax of $0	(53)	33	(134)	13
Comprehensive income	$5,903	$8,877	$10,258	$17,686

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’** EQUITY**

(in thousands, except share data)

For the Three Months Ended September 30, 2026 · · ·
				Accumulated
			Additional	Other
Common Stock · Paid-in · Comprehensive · Accumulated ·
	Shares	Amount	Capital	Loss	Deficit	Total
Balance at June 30, 2026	51,102,687	$5	$1,417,923	$(45)	$(1,279,339)	$138,544
Stock-based compensation	—	—	2,021	—	—	2,021
Shares issued or restricted stock units vested under employee stock plans	586,256	—	146	—	—	146
Unrealized loss on available-for-sale securities	—	—	—	(53)	—	(53)
Net income	—	—	—	—	5,956	5,956
Balance at September 30, 2026	51,688,943	$5	$1,420,090	$(98)	$(1,273,383)	$146,614

For the Three Months Ended September 30, 2025 · ·
				Accumulated
			Additional	Other
Common Stock · Paid-in · Comprehensive · Accumulated ·
	Shares	Amount	Capital	Income (Loss)	Deficit	Total
Balance at June 30, 2025	49,892,725	$5	$1,410,784	$(14)	$(1,306,057)	$104,718
Stock-based compensation	—	—	1,673	—	—	1,673
Shares issued or restricted stock units vested under employee stock plans	491,549	—	—	—	—	—
Unrealized gain on available-for-sale securities	—	—	—	33	—	33
Net income	—	—	—	—	8,844	8,844
Balance at September 30, 2025	50,384,274	$5	$1,412,457	$19	$(1,297,213)	$115,268

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’** EQUITY**

(in thousands, except share data)

For the Nine Months Ended September 30, 2026
Accumulated
Additional · Other
Common Stock · Paid-in · Comprehensive · Accumulated
	Shares	Amount	Capital	Income (Loss)	Deficit	Total
Balance at December 31, 2025	50,408,023	$5	$1,414,074	$36	$(1,283,775)	$130,340
Stock-based compensation	—	—	5,870	—	—	5,870
Shares issued or restricted stock units vested under employee stock plans	1,280,920	—	146	—	—	146
Unrealized loss on available-for-sale securities	—	—	—	(134)	—	(134)
Net income	—	—	—	—	10,392	10,392
Balance at September 30, 2026	51,688,943	$5	$1,420,090	$(98)	$(1,273,383)	$146,614

For the Nine Months Ended September 30, 2025
Accumulated
Additional · Other
Common Stock · Paid-in · Comprehensive · Accumulated
	Shares	Amount	Capital	Income	Deficit	Total
Balance at December 31, 2024	49,105,834	$5	$1,407,000	$6	$(1,314,886)	$92,125
Stock-based compensation	—	—	5,327	—	—	5,327
Shares issued or restricted stock units vested under employee stock plans	1,278,440	—	130	—	—	130
Unrealized gain on available-for-sale securities	—	—	—	13	—	13
Net income	—	—	—	—	17,673	17,673
Balance at September 30, 2025	50,384,274	$5	$1,412,457	$19	$(1,297,213)	$115,268

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.